Anavex Gets FDA Clearance to Proceed With Fragile X Drug Study
Anavex received FDA clearance to proceed with its blarcamesine IND in Fragile X syndrome and plans a Phase 2a study of about 60 patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.